c o m p a n y
play

C O M P A N Y P R E S E N T A T I O N M A Y 2 0 1 8 WHO ARE WE? - PowerPoint PPT Presentation

Mar 12, 2024 •545 likes •826 views

C O M P A N Y P R E S E N T A T I O N M A Y 2 0 1 8 WHO ARE WE? A MEDICAL IMAGING COMPANY WITH ULTRASOUND TECHNOLOGY Unrivaled innovative technology Strategic focus for ultrafast acquisitions and wholly software- Clinical: Breast

  1. C O M P A N Y P R E S E N T A T I O N M A Y 2 0 1 8

  2. WHO ARE WE? • A MEDICAL IMAGING COMPANY WITH ULTRASOUND TECHNOLOGY Unrivaled innovative technology Strategic focus for ultrafast acquisitions and wholly software- ‒ Clinical: Breast and Liver based image formation ‒ Geographic: China, France, United States 54 countries 172 employees 23 Aixplorer product approved including 100 in France patent families Revenue and Cumulative Installed Base 1,900 30,000 1,600 2,000 1,300 25,000 1,000 773 1,500 20,000 541 15,000 352 1,000 209 10,000 64 500 5,000 0 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Cumulative Installed Base Revenue 3

  3. OUR MISSION To become the standard in non-invasive care pathways for breast and liver diseases 4

  4. INNOVATION IN RESPONSE TO A CLINICAL CHALLENGE • A PROVEN TECHNOLOGICAL ADVANCE UltraFast TM Doppler Significantly improved patient throughput THERAPY (15 min vs. 50 min for vascular SCREENING DIAGNOSIS MONITORING examination) • MEASUREMENT OF A NEW UltraFast™ Imaging Real time ShearWave Elastography (SWE™) PARAMETER Up to Real-time, quantitative, any - Tissue stiffness (objective, transducer and any organ 20,000 images/sec reproducible, quantit.) - Replaces manual palpation • NO IONIZING RADIATION Angio PL.U.S. – Planewave ultrasensitive Doppler • NON-INVASIVE Low flow rates in microvessels EXAMINATION without contrast agents • IMPROVED PATIENT THROUGHPUT NEW! TriVu Real time B,SWE, Col+ • ULTRAFAST ACQUISITION simultaneous Real-time combination Anatomy and Function • 3D ACQUISITION 5

  5. HIGH CLINICAL ADDED VALUE FOR A GROWING USER BASE Cumulative total of publications with Aixplorer • GROWING BASE OF CLINICAL DATA (+500 PUBLICATIONS IN PEER-REVIEWED 600 JOURNALS) 500 • EXCELLENT WORLDWIDE NETWORK OF KEY OPINION LEADERS (KOL) 400 • SWE INCORPORATED IN CLINICAL GUIDE 300 LINES (BREAST AND LIVER) 200 • SWE REIMBURSED IN MANY COUNTRIES • VERY POSITIVE FEEDBACK CONCERNING 100 EASE OF USE 0 • MULTIPLE AND REPEAT SALES AT SAME SITE 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 AFTER INITIAL PURCHASE Transformation • HIGH CLINICAL VALUE OF THE TECHNOLOGY RECOGNIZED BY THE FDA : 510K CLEARANCE Technological Innovation FOR LIVER DISEASES , INCLUDING FIBROSIS AND STEATOSIS Clinical Innovation 6

  6. LOCATIONS AND PARTNERSHIP • MORE THAN 2,000 AIXPLORER SYSTEMS INSTALLED WORLDWIDE AND NUMEROUS PRESTIGIOUS PARTNERS 20% 52% 28% Americas/ EMEA Americas EMEA APAC APAC 390 systems 980 systems 530 systems (o/w 280 in the US) (o/w 380 in France) (o/w >390 in China) • CREATION OF A W FOE IN SHANGHAI CLINICAL • ASSESSMENT OF BREAST AND LIVER IN CHINA • - • PRESENCE IN KOREA, CANADA AND TAIW AN, HONG KONG MEXICO SENT FROM THE US • SWITZERLAND, ITALY AND ISRAEL UNDERGOING GROW TH 7

  7. FOCUS • CLINICAL APPLICATIONS ADDRESSING MAJOR PUBLIC HEALTH NEEDS BROAD CLINICAL EXCELLENCE BREAST CANCER • LEADING CAUSE OF CANCER IN • SPECIFICITY OF DIAGNOSIS: BENIGN/MALIGNANT WOMEN: 1 IN 8 WOMEN OBJECTIVITY OF DIAGNOSIS: NOT OPERATOR DEPENDENT • • INCREASE IN NUMBER OF CANCERS: NO RADIATION • - contraception • MONITORING (EVOLUTION OF TUMORS) - • obesity SCREENING OF DENSE BREASTS (>35% WORLD POPULATION) - physical inactivity • SIGNIFICANT DECREASE IN UNNECESSARY BIOPSIES (-47%)* LIVER DISEASES • SPECIFICITY OF DIAGNOSIS: STAGING OF FIBROSIS HEP. B & C – FIBROSIS • • INTERVENTIONAL IMAGING FOR BIOPSIES - 700 million people CANCER SCREENING: BENIGN/MALIGNANT • - Increasing (diabetes, obesity) • NON-INVASIVE FIBROSIS EVALUATION (HEP B & C) • NAFLD – STEATOSIS • STEATOSIS (NASH) DETECTION - 420 million people • REDUCTION IN USE OF CONTRAST AGENTS (ANGIO PL.U.S) - Increasing fast LIVER CANCER • Screening Diagnosis Monitoring SOURCE: COMPANY 8 (*): CLINICAL STUDY BE1

  8. CONTINUUM OF LIVER DISEASES Attenuation Angio SWE SWE UFD SWE Speed of sound PLUS Transplantation Viscosity SWE Liver failure Portal hypertension Angio Healthy liver Simple NASH Fibrosis Cirrhosis PLUS Hepatocellular (Steatohepatitis) steatosis SWE carcinoma Inflammation, ballooning PUSH FROM PHARMA COMPANIES PREVENTION NASH THERAPIES ANTIVIRAL THERAPIES CRITICAL CARE  Early detection of non-alcoholic fatty  Evaluation of liver  Diagnosis of liver fibrosis  Imaging and treatment of liver disease (NAFLD) steatosis hepatocellular carcinoma (HCC) Prediction of cirrhosis complications   Detection of  Detection and treatment of  Selection of patients for treatment inflammation & complications (ascites, PTH, ballooning etc.) Management and monitoring of patients   Diagnosis and  Selection of patients for evaluation of NASH transplantation  Management and monitoring of patients GENERALIST HEPATOLOGY GASTROENTEROLOGY RADIOLOGY 9

  9. A TEC H N OLOGY TH AT C AN BE R EPLIC ATED IN OTH ER C LIN IC AL APPLIC ATION S New cutting-edge technological advances Principal clinical indications for targeted applications Perfusion Perfusion Visualization and evaluation of  Beyond conventional Doppler without use  microvasculature of contrast agents Diagnosis of hepatic lesions without  use of a contrast agent Breast Vascular Vascular Measurement of pulse wave velocity  Simultaneous  indicating vascular elasticity imaging and Improved work flow for quantifying  quantification blood flow rate for better evaluation of cardiovascular diseases Liver Prostate Better analysis of nodules during  early diagnosis SWE helps to target prostate  biopsies to reduce false negatives Musculoskeletal Prostate Musculoskeletal Real-time visualization of anatomy  and functional image of muscle and Improved Improved   tendons biopsy diagnosis guidance 10

  10. F I N A N C I A L D A T A

  11. SOLID GROWTH IN 2017 In thousands of euros 2017 2016 Change (%) • +11% sales growth (+13% constant Products 21,827 20,073 +9% currency) Services 2,869 2,143 +34% • Strong product (+10%*) and service TOTAL SALES 24,695 22,217 +11% (+35%*) performance SALES GEOGRAPHIC DISTRIBUTION 2016 2017 • Tremendous growth in china (+33%*) and France (+16%) EMEA 8,192 • 18%* decline in the united states 9,579 10,310 10,816 37% America 43% 42% 44% Asia 4,446 • Asia and EMEA regions improved 3,569 20% 14% respectively by +29%* and +13% over the year France 5,104 4,403 • Direct sales, which include china, 8,905 21% 20% 7,969 US France and the united states, 36% 36% 3,199 4,048 represent 64% of sales revenues in 13% China 18% 2017, against 64% in 2016 7,487 5,797 RoW 30% 26% (*)=% at constant rate 12

  12. SIGNIFICANT EBITDA IMPROVEMENT • INCREASE IN GROSS MARGIN AND SIGNIFICANT EBITDA IMPROVEMENT 11% sales growth 31/12/2017 31/12/2016  Var. In thousands of euros Sales 24,695 22,217 +11.2% gross margin rate on sales improvement:  - 1,023 - Other revenue +1.7pt 24,695 23,240 +6.3% Total revenue control of OPEX with €21.0m vs. 20.9m in  -13,608 -12,628 +7.8% Cost of sales 2016 Gross margin 1 11,088 10,611 +4.5% intensification of R&D efforts in accordance  11,088 9,588 +15.6% Gross margin on sales 2 with next platform’s development phasing with 44.9% 43.2% +1.7pt €9.8m spent (€2.6m net of RTC and Gross margin as a % of sales activation) vs €9.1m in 2016 Research and development -2,558 -3,046 expenses EBITDA improvement of +€1.2m  -12,341 -11,987 Selling and marketing expenses improvement in the operating result with  General and administrative -5,775 -5,447 expenses €(9.9m) vs. €(10.3m) in 2016 (-40% vs. -46% Other operating -294 -403 of sales) income/(expense) -20,968 -20,883 Total OPEX - €2.2m decrease in financial result  EBITDA -6,611 -7,805 +15.3% - € 0.9m for early Norgine loan repayment and interests on -9,880 -10,272 +3.8% Core operating result repayable advance, non-recurring charge specific to 2017 Operating result -9,880 -10,272 +3.8% - €0.8m due to exchange gain on 2016 and loss on 2017 Financial result -2,405 -221 - €0.4m due to rise in financial interests - -12,247 -10,555 -16.0% Net profit/(loss) (1) GROSS MARGIN ON SALES = SALES - COST OF SALES 13 (2) GROSS MARGIN ON SALES = SALES - GROSS MARGIN ON SALES/SALES

Recommend

More recommend